ContextTumor necrosis factor (TNF) plays an important role in host defense and tumor
growth control. Therefore, anti-TNF antibody therapies may increase the risk of serious
infections and malignancies. ObjectiveTo assess the extent to which anti-TNF antibody
therapies may increase the risk of serious infections and malignancies in patients with
rheumatoid arthritis by performing a meta-analysis to derive estimates of sparse harmful
events occurring in randomized trials of anti-TNF therapy. Data SourcesA systematic …